Cardiology Associates Research. LLC

Tupelo, Mississippi 38801

3 studies enrolling now · 28 studies all time

What they study most

Acute Coronary Syndromes, Arteriosclerosis, Atherosclerotic Cardiovascular Disease, Atrial Fibrillation, Atrioventricular Block, Bradycardia, Cardiac Disease, Cardiovascular Disease, Cardiovascular Diseases, Congestive Heart Failure, Coronary Artery Disease, Coronary Disease

Studies at this site

• OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events — Recruiting now
• CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis — Recruiting now
• A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) — Recruiting now
• MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions — Recruiting now
• SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System — Completed
• BIOTRONIK Conduction System Pacing With the Solia Lead - Solia CSP S — Completed
• Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD — Running, not enrolling
• Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial — Running, not enrolling
• A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD) — Completed
• Hybrid Ablation Plus Medical Therapy for Persistent Atrial Fibrillation — Completed
• SPYRAL PIVOTAL - SPYRAL HTN-OFF MED Study — Completed
• WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2 — Stopped early
• EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction) — Completed
• A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke — Stopped early
• Global Prevalence of ATTR-CM in Participants With HFpEF — Stopped early
• Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study — Completed
• Repository of Phase Signals for Pulmonary Hypertension Algorithm Development — Status unconfirmed
• CONVERGE - Epi/Endo Ablation For Treatment of Persistent Atrial Fibrillation(AF) — Completed
• A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure — Completed
• CONVERGE CAP Study-For The Treatment Of Symptomatic Persistent or Long-standing Persistent AF — Withdrawn before enrolling
• Scoreflex NC - Scoring PTCA Catheter — Completed
• A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart — Completed
• A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• The Dual Antiplatelet Therapy Study (DAPT Study) — Completed
• Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke — Completed
• Study Effect of VIA-2291 on Vascular Inflammation — Completed